Wells Fargo Upgrades Celldex Therapeutics to Equal-Weight, Announces $27 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has upgraded Celldex Therapeutics from Underweight to Equal-Weight and set a price target of $27.
November 10, 2023 | 11:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Celldex Therapeutics has been upgraded by Wells Fargo from Underweight to Equal-Weight with a new price target of $27.
The upgrade from Underweight to Equal-Weight by Wells Fargo indicates a more positive outlook for Celldex Therapeutics. The new price target of $27 also suggests that the analyst sees potential for the stock's price to increase. This could lead to a positive short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100